Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Pediatrics and Neonatology
  • Pediatrics and Neonatology News
  • Erythropoietin not...

Erythropoietin not beneficial for hypoxic-ischemic encephalopathy in newborns: NEJM

Written by Jacinthlyn Sylvia Published On 2022-07-15T04:00:34+05:30  |  Updated On 2022-07-15T06:13:46+05:30
Erythropoietin not beneficial for hypoxic-ischemic encephalopathy in newborns: NEJM

USA: In a new study conducted by Yvonne W. Wu and colleagues it has been found that, erythropoietin administration did not reduce the risk of mortality or neurodevelopmental damage in babies undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy, and it was also linked to a greater rate of major adverse events.Putting it simplistically, adding erythropoietin to cooling therapy...

USA: In a new study conducted by Yvonne W. Wu and colleagues it has been found that, erythropoietin administration did not reduce the risk of mortality or neurodevelopmental damage in babies undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy, and it was also linked to a greater rate of major adverse events.

Putting it simplistically, adding erythropoietin to cooling therapy for term newborns with birth asphyxia has no benefit over cooling therapy alone.

The findings of the study were published in The New England Journal of Medicine.

In addition to being a significant cause of death, neonatal hypoxic-ischemic encephalopathy also leaves survivors with long-term disabilities. It has been speculated that erythropoietin may have neuroprotective benefits in newborns with hypoxic-ischemic encephalopathy, but it is uncertain if this treatment when combined with therapeutic hypothermia, may affect neurodevelopmental outcomes. This study was carried out in order to determine the impact of erythropoietin while jogging in conjunction with therapeutic hypothermia.

501 children were randomly allocated with moderate or severe hypoxic-ischemic encephalopathy born at 36 weeks or more gestation to receive erythropoietin or a placebo along with routine therapeutic hypothermia in a multicenter, randomized, double-blind, placebo-controlled study. Within 26 hours of delivery, as well as at 2, 3, and 4 days old, intravenous erythropoietin (1000 U per kilogram of body weight) or saline placebo was given.

At 22 to 36 months of age, the main result was either death or neurodevelopmental disability. Cerebral palsy, a Gross Motor Function Classification System level of at least 1 (on a scale from 0 [normal] to 5 [most impaired]), or a cognitive score of less than 90 (corresponding to 0.67 SD below the mean) on the Bayley Scales of Infant and Toddler Development, were all considered to be signs of neurodevelopmental impairment. Higher scores indicated better performance.

The key findings of this study were as follows:

1. The modified intention-to-treat analysis included 500 babies, of which 257 got erythropoietin and 243 received a placebo.

2. In the erythropoietin group, there were 52.5% deaths or neurodevelopmental impairments, compared to 49.5% in the placebo group.

3. In comparison to the placebo group, there were more significant adverse events on average per kid in the erythropoietin group.

Reference:

Wu, Y. W., Comstock, B. A., Gonzalez, F. F., Mayock, D. E., Goodman, A. M., Maitre, N. L., Chang, T., Van Meurs, K. P., Lampland, A. L., Bendel-Stenzel, E., Mathur, A. M., Wu, T.-W., Riley, D., Yanowitz, T. D., … Juul, S. E. (2022). Trial of Erythropoietin for Hypoxic–Ischemic Encephalopathy in Newborns. New England Journal of Medicine, 387(2), 148–159. https://doi.org/10.1056/NEJMoa2119660

Erythropoietin hypothermia neonatal encephalopathy New England Journal of Medicine newborns 
Source : New England Journal of Medicine
Jacinthlyn Sylvia
Jacinthlyn Sylvia

    Neuroscience Masters graduate

    Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok